We studied the effect of subconjunctival injections ofmethotrexate (MTX) in 18 patients with non-infectious ocular inflammatory processes (unilateral anterior uveitis 1 1 patients, corneal graft rejection 3 patients, nodular sclerouveitis with no systemic disease 2 patients, Vogt-Koyanagi-Harada's disease 1 patient, and Behcet's disease 1 patient). Weekly subconjunctival injections of 7.Smg of MTX were given. Daily slit lamp examination was performed to evaluate the degree of in_flammatory activi(y in the anterior chamber or sclera and conjunctiva during the treatment. Patients were clinically followed for an average of 7.8 months (3 to .12 months) and no patient had evidence of local or systemic side effects. The conjunctiva remained yellowish and edematous for approximately 24hs after the injections and returned to the previous aspect after that. Our results showed that subconjunctival weekly injections oflow dose MTX have a favorable response in the treatment in nine of 1 1 cases of anterior uveitis, three cases of corneal graft rejection, and one patient of Vogt-Koyanagi-Harada disease. One patient with Behcet disease, and two with scleritis did not respond to the treatment.
[1]
B. Cronstein,et al.
The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.
,
1993,
The Journal of clinical investigation.
[2]
C. Lowder,et al.
Low-dose methotrexate therapy for ocular inflammatory disease.
,
1992,
Ophthalmology.
[3]
J. Doroshow,et al.
Ocular irritation from high‐dose methotrexate therapy: Pharmacokinetics of drug in the tear film
,
1981,
Cancer.
[4]
V. Jones,et al.
Intra-articular methotrexate. Clinical and laboratory study in rheumatoid and psoriatic arthritis.
,
1978,
Annals of the rheumatic diseases.